Replies to post #105454 on Biotech Values

[biomaven0]

I was just basing it on the $40m profit (based on a 10% profit share) for MNTA that seems to be the consensus in the 2-way plus authorized generic case, and assuming Teva's COG and sales costs are similar to those of Sandoz.

So to answer your question, it's based on whatever tL revenue leads to $40m income to MNTA in this 2+1 case. :)

Peter